Larvol Delta - Remission-and-Lupus-Low-Disease-Activity-State-Attainment-and-Glucocorticoid-Reduction-without-Increasing-Flares-with-Anifrolumab-in-Asian-patients-with-Systemic-Lupus-Erythematosus-A-Post-Hoc-Analysis-from-a-Phase-III-Study

Saphnelo (anifrolumab-fnia) - AstraZeneca

https://acrconvergence2026.eventscribe.net/fsPopup.asp?PresentationID=1898729&mode=presInfo

Eric F. Morand, PhD, MBBS

Sep 8, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next